<DOC>
	<DOCNO>NCT00049504</DOCNO>
	<brief_summary>This phase II trial study well give fludarabine phosphate , cyclophosphamide , tacrolimus , mycophenolate mofetil total-body irradiation together donor bone marrow transplant work treat patient high-risk hematologic cancer . Giving low dos chemotherapy , fludarabine phosphate cyclophosphamide , total-body irradiation donor bone marrow transplant help stop growth cancer cell stop divide kill . Giving cyclophosphamide transplant may also stop patient 's immune system reject donor 's bone marrow stem cell . The donated stem cell may replace patient 's immune system cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus mycophenolate mofetil transplant may stop happen</brief_summary>
	<brief_title>Fludarabine Phosphate , Cyclophosphamide , Tacrolimus , Mycophenolate Mofetil , Total-Body Irradiation , Donor Bone Marrow Transplant Treating Patients With High-Risk Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . To determine engraftment achieve safely patient high-risk hematologic malignancy undergo non-myeloablative bone marrow transplantation ( BMT ) human leukocyte antigen ( HLA ) -haploidentical donor . OUTLINE : NONMYELOABLATIVE CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) 1 hour day -6 -2 cyclophosphamide IV 1 hour day -6 -5 . Patients undergo total body irradiation day -1 . TRANSPLANTATION : Patients undergo BMT , HLA-haploidentical donor , day 0 . POST-TRANSPLANT IMMUNOSUPPRESSION : Patients receive cyclophosphamide IV 1 hour day 3 . GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS : Patients receive tacrolimus IV 1-2 hour tacrolimus orally ( PO ) , tolerate , day 4-180 , taper day 86 absence graft-versus-host disease . Patients also receive mycophenolate mofetil PO three time daily day 4-35 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 6 month annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Chronic myeloid leukemia ( CML ) accelerate phase ( AP ) Acute myeloid leukemia ( AML ) highrisk cytogenetics [ del ( 5q ) /5 , del ( 7q ) /7 , abnormal 3q , 9q , 11q , 20q , 21q , 17p , ( 6:9 ) , ( 9 ; 22 ) , complex karyotype ( &gt; = 3 abnormality ) ] complete remission ( CR ) 1 AML &gt; = CR2 ; patient &lt; 5 % marrow blast time transplant Highrisk ALL define : CR1 highrisk cytogenetics ; ( 9 ; 22 ) , ( 4 ; 11 ) , hypodiploid ( &lt; 45 chromosome ) pediatric patient ; ( 9 ; 22 ) , ( 8 ; 14 ) , ( 4 ; 11 ) , ( 1 ; 19 ) adult patient ; &gt; 4 wk achieve CR1 ; &gt; = CR2 ( patient &lt; 5 % marrow blast time transplant ) Myelodysplastic syndrome ( MDS ) ( &gt; int1 per IPSS ) &gt; = 1 prior cycle induction chemotherapy ; &lt; 5 % marrow blast time transplant Multiple myeloma ( MM ) Stage II III patient progress initial response chemotherapy autologous hematopoietic stem cell transplantation ( HSCT ) MM patient refractory disease may benefit tandem autologousnonmyeloablative allogeneic transplant Chronic lymphocytic leukemia ( CLL ) , nonHodgkin 's lymphoma ( NHL ) Hodgkin 's Disease ( HD ) ineligible autologous HSCT resistant/refractory disease may benefit tandem autologous nonmyeloablative allogeneic transplant Patients receive prior allogeneic HSCT either reject graft become tolerant graft active graftversushost disease ( GvHD ) require immunosuppressive therapy DONOR : Related donor identical one HLA haplotype mismatch HLAA , B , C DRB1 locus unshared haplotype exception single HLAA , B C allele mismatch Crossmatch positive donor Patients suitably match related unrelated donor Patients conventional transplant option ( conventional transplant priority eligible patient = &lt; 50 yr age relate donor mismatch single HLAA , B DRB1 antigen ) Central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Presence active , serious infection ( e.g. , mucormycosis , uncontrolled aspergillosis , tuberculosis ) Karnofsky Performance Status &lt; 60 adult patient LanskyPlay Performance Score &lt; 60 pediatric patient Left ventricular ejection fraction &lt; 35 % Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 35 % and/or receive supplemental continuous oxygen Liver abnormality : fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL symptomatic biliary disease Human immunodeficiency virus ( HIV ) positive patient Women childbearing potential pregnant ( betaHCG+ ) breast feed Fertile men woman unwilling use contraceptive 12 month posttransplant Life expectancy severely limited disease malignancy DONOR : Donorrecipient pair HLAmismatch HVG direction DONOR : Crossmatch positive recipient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>